Hemoptysis during concomitant treatment with rivaroxaban and amiodarone in a patient with a history of pulmonary disease;Krwioplucie w trakcie jednoczesnego leczenia rywaroksabanem i amiodaronem u chorego z obciążonym wywiadem płucnym

Polski Merkuriusz Lekarski

Volumn 39, Issue 232, 2015, Pages 227-230

  Elikowski, Waldemar ^a   Małek, Małgorzata ^a   Skowroński, Marcin ^b   Wróblewski, Dariusz ^a   Skrzywanek, Paweł ^a   Zawilska, Krystyna ^c  

^a Jozef Strus Hospital   (Poland)

^b Wielkopolska Center of Pulmonology and Thoracic Surgery   (Poland)

^c Diagnostic and Treatment Centre INTERLAB   (Poland)

Author keywords

amiodarone; hemoptysis; history of pulmonary disease; rivaroxaban

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; RIVAROXABAN;

AGED; ATRIAL FIBRILLATION; BRONCHIECTASIS; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; HEMOPTYSIS; HUMAN; MALE; RADIOGRAPHY; VENOUS THROMBOEMBOLISM;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BRONCHIECTASIS; DRUG THERAPY, COMBINATION; FACTOR XA INHIBITORS; HEMOPTYSIS; HUMANS; MALE; RIVAROXABAN; VENOUS THROMBOEMBOLISM;

EID: 84954599342     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bauersachs R, Berkowitz SD, Brenner B, et al.: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010; 363: 2499-2510.
2. Borders CW 3rd, Bennett S, Mount C, et al.: A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med, 2012; 177: 118-120.
3. Bruzzi JF, Rémy-Jardin M, Delhaye D, et al.: Multi-detector row CT of hemoptysis. Radio Graphics, 2006; 26: 3-22.
4. Camm AJ, Lip GY, De Caterina R, et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with special contribution of the European Heart Rhythm Association. Eur Heart J, 2012; 33: 2719-2747.
5. Elikowski W, Cofta S, Nowicki A, et al.: Recurrent hemoptysis following thienopyridines and amiodarone administration. Therapeutic dilemma. Pol Arch Med Wewn, 2005; 114: 773-778.
6. Goodman SG, Wojdyla DM, Piccini JP, et al.: Factors associated with major bleeding events: insights from the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 891-900. ho
7. , 7. Heidbuchel H, Verhamme P, Alings M, et al.: European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013; 15: 625-651. om.pl/s
8. Heimark LD, Wienkers L, Kunze K, et al.: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther, 1992; 51: 398-407. press.c
9. Jackevicius CA, Tom A, Essebag V, et al.: Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol, 2011; 108: 705-710. me
10. Jean-Baptiste E.: Clinical assessment and management of massive hemoptysis. Crit Care Med, 2000; 28: 1642-1647.
11. Konkle BA.: Monitoring target specific oral anticoagulants. Hematology. Am Soc Hematol Edu Program, 2014; 329-333.
12. Lee J, Park YS, Lee C-H, et al.: Antiplatelet or anticoagulant therapy might not increase the risk of haemoptysis in patients with bronchiectasis. Int J Tuberc Lung Dis, 2013; 17: 989-991.
13. Maves R, Phull H, Copeland D, et al.: Fatal diffuse alveolar hemorrhage and hypoxemic respiratory failure associated with rivaroxaban. Crit Care Med, 2014; 42: p A1662.
14. McNeil KD, Firouz-Abadi A, Oliver W, et al.: Amiodarone pulmonary toxicity – three unusual manifestations. Aust N Z J Med, 1992; 22: 14-18.
15. Papiris SA, Triantafillidou C, Kolilekas L, et al.: Amiodarone: review of pulmonary effects and toxicity. Drug Saf, 2010; 33: 539-558.
16. Patel MR, Mahaffey KW, Garg J, et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
17. Ravishankar R, Samuels LE, Kaufman MS, et al.: Amiodarone-associated hemoptysis. Am J Med Sci, 1998; 316: 390-392.
18. Soares Pires F, Teixeira N, Coelho F, et al.: Hemoptysis – etiology, evaluation, and treatment in a university hospital. Rev Port Pneumol, 2010; 17: 7-14.
19. Steinberg BA, Hellkamp AS, Lokhnygia Y, et al.: Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm, 2014; 11: 925-932.
20. Tanawuttiwat T, Harindhanavudhi T, Hanif S, et al.: Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ, 2010; 19: 435-437.
21. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest, 1994; 105: 305-306.
22. Xarelto Product Monograph, Bayer Inc. Date of revision: August 28, 2013.